{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:48:45Z","timestamp":1783039725278,"version":"3.54.6"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82004280"],"award-info":[{"award-number":["82004280"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82104797"],"award-info":[{"award-number":["82104797"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81611-8","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:36:50Z","timestamp":1733409410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A multi-omics approach identifies the key role of disorders of sphingolipid metabolism in Ang II-induced hypertensive cardiomyopathy myocardial remodeling"],"prefix":"10.1038","volume":"14","author":[{"given":"Yiwei","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dufang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaizhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"issue":"1","key":"81611_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","volume":"7","author":"GM Felker","year":"2022","unstructured":"Felker, G. M. et al. Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol. 7(1), 26\u201334 (2022).","journal-title":"JAMA Cardiol."},{"issue":"5","key":"81611_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/HYPERTENSIONAHA.123.22504","volume":"81","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Identification of circulating plasma proteins as a mediator of hypertension-driven cardiac remodeling: a mediation mendelian randomization study. Hypertension 81(5), 1132\u20131144 (2024).","journal-title":"Hypertension"},{"issue":"1","key":"81611_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1532-429X-14-28","volume":"14","author":"AM Maceira","year":"2012","unstructured":"Maceira, A. M. & Mohiaddin, R. H. Cardiovascular magnetic resonance in systemic hypertension. J. Cardiovasc. Magn. Reson. 14(1), 28 (2012).","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"5","key":"81611_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s44161-022-00057-1","volume":"1","author":"W Wang","year":"2022","unstructured":"Wang, W. et al. Metabolic characterization of hypertrophic cardiomyopathy in human heart. Nat. Cardiovasc. Res. 1(5), 445\u2013461 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"issue":"1","key":"81611_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pcad.2019.11.009","volume":"63","author":"M Yildiz","year":"2020","unstructured":"Yildiz, M. et al. Left ventricular hypertrophy and hypertension. Prog. Cardiovasc. Dis. 63(1), 10\u201321 (2020).","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"12","key":"81611_CR6","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1161\/HYPERTENSIONAHA.123.21427","volume":"80","author":"A Liu","year":"2023","unstructured":"Liu, A. et al. ESCRT-III component CHMP4C attenuates cardiac hypertrophy by targeting the endo-lysosomal degradation of EGFR. Hypertension 80(12), 2674\u20132686 (2023).","journal-title":"Hypertension"},{"issue":"18","key":"81611_CR7","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1042\/CS20171167","volume":"131","author":"QQ Wu","year":"2017","unstructured":"Wu, Q. Q. et al. Mechanisms contributing to cardiac remodelling. Clin. Sci. (Lond) 131(18), 2319\u20132345 (2017).","journal-title":"Clin. Sci. (Lond)"},{"issue":"6","key":"81611_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","volume":"117","author":"NG Frangogiannis","year":"2021","unstructured":"Frangogiannis, N. G. Cardiac fibrosis. Cardiovasc. Res. 117(6), 1450\u20131488 (2021).","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"81611_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","volume":"118","author":"JG Travers","year":"2016","unstructured":"Travers, J. G. et al. Cardiac Fibrosis: the fibroblast awakens. Circ. Res. 118(6), 1021\u20131040 (2016).","journal-title":"Circ. Res."},{"issue":"7","key":"81611_CR10","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/0735-1097(89)90360-4","volume":"13","author":"KT Weber","year":"1989","unstructured":"Weber, K. T. Cardiac interstitium in health and disease: the fibrillar collagen network. J. Am. Coll. Cardiol. 13(7), 1637\u20131652 (1989).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"81611_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1096\/fj.13-227579","volume":"28","author":"SL Wilson","year":"2014","unstructured":"Wilson, S. L. et al. A microscopic and macroscopic study of aging collagen on its molecular structure, mechanical properties, and cellular response. FASEB J. 28(1), 14\u201325 (2014).","journal-title":"FASEB J."},{"issue":"1","key":"81611_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.111.243162","volume":"110","author":"NG Frangogiannis","year":"2012","unstructured":"Frangogiannis, N. G. Regulation of the inflammatory response in cardiac repair. Circ. Res. 110(1), 159\u2013173 (2012).","journal-title":"Circ. Res."},{"issue":"12","key":"81611_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.jacbts.2023.05.008","volume":"8","author":"X Li","year":"2023","unstructured":"Li, X. et al. TAK1 activation by NLRP3 deficiency confers cardioprotection against pressure overload-induced cardiomyocyte pyroptosis and hypertrophy. JACC Basic Transl. Sci. 8(12), 1555\u20131573 (2023).","journal-title":"JACC Basic Transl. Sci."},{"key":"81611_CR14","doi-asserted-by":"crossref","unstructured":"Ghazi, L. & Drawz, P. Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy. F1000Res 6 (2017).","DOI":"10.12688\/f1000research.9692.1"},{"issue":"2","key":"81611_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jvim.15454","volume":"33","author":"MK Ames","year":"2019","unstructured":"Ames, M. K., Atkins, C. E. & Pitt, B. The renin-angiotensin-aldosterone system and its suppression. J. Vet. Intern. Med. 33(2), 363\u2013382 (2019).","journal-title":"J. Vet. Intern. Med."},{"key":"81611_CR16","doi-asserted-by":"publisher","first-page":"107680","DOI":"10.1016\/j.exer.2019.05.020","volume":"186","author":"KM Mirabito Colafella","year":"2019","unstructured":"Mirabito Colafella, K. M., Bov\u00e9e, D. M. & Danser, A. H. J. The renin-angiotensin-aldosterone system and its therapeutic targets. Exp. Eye Res. 186, 107680 (2019).","journal-title":"Exp. Eye Res."},{"issue":"12","key":"81611_CR17","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1042\/CS20200249","volume":"134","author":"S Li","year":"2020","unstructured":"Li, S. et al. TRIF\/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling. Clin. Sci. (Lond) 134(12), 1319\u20131331 (2020).","journal-title":"Clin. Sci. (Lond)"},{"issue":"1","key":"81611_CR18","doi-asserted-by":"publisher","first-page":"16342","DOI":"10.1038\/s41598-018-34211-2","volume":"8","author":"TW Emans","year":"2018","unstructured":"Emans, T. W. et al. Angiotensin II-induced hypertension in rats is only transiently accompanied by lower renal oxygenation. Sci. Rep. 8(1), 16342 (2018).","journal-title":"Sci. Rep."},{"issue":"1","key":"81611_CR19","doi-asserted-by":"publisher","first-page":"e010418","DOI":"10.1161\/JAHA.118.010418","volume":"8","author":"G She","year":"2019","unstructured":"She, G. et al. K(Ca)3.1 channels promote cardiac fibrosis through mediating inflammation and differentiation of monocytes into myofibroblasts in angiotensin II-treated rats. J. Am. Heart Assoc. 8(1), e010418 (2019).","journal-title":"J. Am. Heart Assoc."},{"issue":"42","key":"81611_CR20","doi-asserted-by":"publisher","first-page":"72302","DOI":"10.18632\/oncotarget.20305","volume":"8","author":"ZZ Zhang","year":"2017","unstructured":"Zhang, Z. Z. et al. The sirtuin 6 prevents angiotensin II-mediated myocardial fibrosis and injury by targeting AMPK-ACE2 signaling. Oncotarget 8(42), 72302\u201372314 (2017).","journal-title":"Oncotarget"},{"issue":"17","key":"81611_CR21","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S. et al. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34(17), i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"issue":"4","key":"81611_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12(4), 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"issue":"3","key":"81611_CR23","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/gb-2011-12-3-r22","volume":"12","author":"A Roberts","year":"2011","unstructured":"Roberts, A. et al. Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol. 12(3), R22 (2011).","journal-title":"Genome Biol."},{"issue":"2","key":"81611_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics 31(2), 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"issue":"12","key":"81611_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15(12), 550 (2014).","journal-title":"Genome Biol."},{"issue":"6","key":"81611_CR26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.111.172700","volume":"57","author":"M Kurdi","year":"2011","unstructured":"Kurdi, M. & Booz, G. W. New take on the role of angiotensin II in cardiac hypertrophy and fibrosis. Hypertension 57(6), 1034\u20131038 (2011).","journal-title":"Hypertension"},{"issue":"3","key":"81611_CR27","doi-asserted-by":"publisher","first-page":"H1900","DOI":"10.1152\/ajpheart.00379.2007","volume":"293","author":"J Xu","year":"2007","unstructured":"Xu, J. et al. Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 293(3), H1900\u2013H1907 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"81611_CR28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/cvr\/cvn230","volume":"81","author":"JF Ainscough","year":"2009","unstructured":"Ainscough, J. F. et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc. Res. 81(3), 592\u2013600 (2009).","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"81611_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41598-019-57230-z","volume":"10","author":"Q Luo","year":"2020","unstructured":"Luo, Q. et al. Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension. Sci. Rep. 10(1), 349 (2020).","journal-title":"Sci. Rep."},{"issue":"10","key":"81611_CR30","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","volume":"128","author":"WJ Paulus","year":"2021","unstructured":"Paulus, W. J. & Zile, M. R. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ. Res. 128(10), 1451\u20131467 (2021).","journal-title":"Circ. Res."},{"issue":"1","key":"81611_CR31","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1038\/s41598-022-08561-x","volume":"12","author":"A Larson","year":"2022","unstructured":"Larson, A. et al. Altered intercellular communication and extracellular matrix signaling as a potential disease mechanism in human hypertrophic cardiomyopathy. Sci. Rep. 12(1), 5211 (2022).","journal-title":"Sci. Rep."},{"key":"81611_CR32","doi-asserted-by":"crossref","unstructured":"Schlittler, M. et al. Myocardial fibrosis in hypertrophic cardiomyopathy: a perspective from fibroblasts. Int. J. Mol. Sci. 24(19) (2023).","DOI":"10.3390\/ijms241914845"},{"issue":"2","key":"81611_CR33","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1073\/pnas.97.2.931","volume":"97","author":"P Paradis","year":"2000","unstructured":"Paradis, P. et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Natl. Acad. Sci. USA 97(2), 931\u2013936 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"81611_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/01.RES.73.3.413","volume":"73","author":"J Sadoshima","year":"1993","unstructured":"Sadoshima, J. & Izumo, S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ. Res. 73(3), 413\u2013423 (1993).","journal-title":"Circ. Res."},{"issue":"10","key":"81611_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1157\/13093982","volume":"59","author":"B L\u00f3pez Salazar","year":"2006","unstructured":"L\u00f3pez Salazar, B. et al. Altered fibrillar collagen metabolism in hypertensive heart failure. Current understanding and future prospects. Rev. Esp. Cardiol. 59(10), 1047\u20131057 (2006).","journal-title":"Rev. Esp. Cardiol."},{"issue":"3","key":"81611_CR36","doi-asserted-by":"publisher","first-page":"H610","DOI":"10.1152\/ajpheart.00070.2018","volume":"315","author":"LB Steffensen","year":"2018","unstructured":"Steffensen, L. B. & Rasmussen, L. M. A role for collagen type IV in cardiovascular disease? Am. J. Physiol. Heart Circ. Physiol. 315(3), H610\u2013H625 (2018).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"81611_CR37","doi-asserted-by":"crossref","unstructured":"Pozzi, A., Yurchenco, P. D. & Iozzo, R. V. The nature and biology of basement membranes. Matrix Biol., 57\u201358 (2017).","DOI":"10.1016\/j.matbio.2016.12.009"},{"key":"81611_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mehy.2017.03.031","volume":"103","author":"IA Mohamed","year":"2017","unstructured":"Mohamed, I. A., El-Badri, N. & Zaher, A. Dilated cardiomyopathy-induced disruption of basement membrane alters the lever systems acting on the heart. Med. Hypotheses 103, 46\u201350 (2017).","journal-title":"Med. Hypotheses"},{"key":"81611_CR39","doi-asserted-by":"crossref","unstructured":"Boland, E., Quondamatteo, F. & Van Agtmael, T. The role of basement membranes in cardiac biology and disease. Biosci. Rep., 41(8) (2021).","DOI":"10.1042\/BSR20204185"},{"issue":"3","key":"81611_CR40","doi-asserted-by":"publisher","first-page":"H1364","DOI":"10.1152\/ajpheart.00355.2006","volume":"292","author":"HK Graham","year":"2007","unstructured":"Graham, H. K. & Trafford, A. W. Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure. Am. J. Physiol. Heart Circ. Physiol. 292(3), H1364\u2013H1372 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"81611_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-023-01732-w","volume":"9","author":"S Song","year":"2024","unstructured":"Song, S. et al. TEA domain transcription factor 1(TEAD1) induces cardiac fibroblasts cells remodeling through BRD4\/Wnt4 pathway. Signal. Transduct. Target. Ther. 9(1), 45 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"3","key":"81611_CR42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jgg.2023.06.006","volume":"51","author":"J Mu","year":"2024","unstructured":"Mu, J., Lam, S. M. & Shui, G. Emerging roles and therapeutic potentials of sphingolipids in pathophysiology: emphasis on fatty acyl heterogeneity. J. Genet. Genom. 51(3), 268\u2013278 (2024).","journal-title":"J. Genet. Genom."},{"key":"81611_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-981-19-0394-6_6","volume":"1372","author":"Y Hu","year":"2022","unstructured":"Hu, Y. & Dai, K. Sphingosine 1-phosphate metabolism and signaling. Adv. Exp. Med. Biol. 1372, 67\u201376 (2022).","journal-title":"Adv. Exp. Med. Biol."},{"key":"81611_CR44","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.phrs.2020.104793","volume":"156","author":"E Jozefczuk","year":"2020","unstructured":"Jozefczuk, E., Guzik, T. J. & Siedlinski, M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol. Res. 156, 104793 (2020).","journal-title":"Pharmacol. Res."},{"key":"81611_CR45","doi-asserted-by":"crossref","unstructured":"Cartier, A. & Hla, T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. Science 366(6463) (2019).","DOI":"10.1126\/science.aar5551"},{"issue":"6","key":"81611_CR46","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1210\/me.2014-1388","volume":"29","author":"PC Wilson","year":"2015","unstructured":"Wilson, P. C. et al. Inhibition of sphingosine kinase 1 ameliorates angiotensin II-induced hypertension and inhibits transmembrane calcium entry via store-operated calcium channel. Mol. Endocrinol. 29(6), 896\u2013908 (2015).","journal-title":"Mol. Endocrinol."},{"key":"81611_CR47","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3389\/fphar.2018.01504","volume":"9","author":"E Wang","year":"2018","unstructured":"Wang, E., He, X. & Zeng, M. The role of S1P and the related signaling pathway in the development of tissue fibrosis. Front. Pharmacol. 9, 1504 (2018).","journal-title":"Front. Pharmacol."},{"key":"81611_CR48","doi-asserted-by":"publisher","first-page":"109861","DOI":"10.1016\/j.cellsig.2020.109861","volume":"78","author":"C Donati","year":"2021","unstructured":"Donati, C. et al. Role of sphingosine 1-phosphate signalling in tissue fibrosis. Cell Signal. 78, 109861 (2021).","journal-title":"Cell Signal."},{"issue":"2","key":"81611_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7150\/ijbs.8.195","volume":"8","author":"E Pardali","year":"2012","unstructured":"Pardali, E. & Ten Dijke, P. TGF\u03b2 signaling and cardiovascular diseases. Int. J. Biol. Sci. 8(2), 195\u2013213 (2012).","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"81611_CR50","first-page":"99","volume":"21","author":"W Jachec","year":"2008","unstructured":"Jachec, W. et al. Expression of TGF-beta1 and its receptor genes (TbetaR I, TbetaR II, and TbetaR III-betaglycan) in peripheral blood leucocytes in patients with idiopathic pulmonary arterial hypertension and Eisenmenger\u2019s syndrome. Int. J. Mol. Med. 21(1), 99\u2013107 (2008).","journal-title":"Int. J. Mol. Med."},{"key":"81611_CR51","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.12659\/MSM.910707","volume":"24","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Transforming growth factor \u03b21 (TGF-\u03b21) appears to promote coronary artery disease by upregulating sphingosine kinase 1 (SPHK1) and further upregulating its downstream TIMP-1. Med. Sci. Monit. 24, 7322\u20137328 (2018).","journal-title":"Med. Sci. Monit."},{"issue":"4","key":"81611_CR52","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1042\/BCJ20210777","volume":"479","author":"Z Cheng","year":"2022","unstructured":"Cheng, Z. FoxO transcription factors in mitochondrial homeostasis. Biochem. J. 479(4), 525\u2013536 (2022).","journal-title":"Biochem. J."},{"key":"81611_CR53","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhou, Y. & Graves, D. T. FOXO transcription factors: their clinical significance and regulation. Biomed Res. Int. 2014, 925350 (2014).","DOI":"10.1155\/2014\/925350"},{"key":"81611_CR54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.yjmcc.2014.03.001","volume":"73","author":"AC K\u00f6hler","year":"2014","unstructured":"K\u00f6hler, A. C., Sag, C. M. & Maier, L. S. Reactive oxygen species and excitation-contraction coupling in the context of cardiac pathology. J. Mol. Cell. Cardiol. 73, 92\u2013102 (2014).","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"5","key":"81611_CR55","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41388-023-02907-z","volume":"43","author":"FR Palma","year":"2024","unstructured":"Palma, F. R. et al. ROS production by mitochondria: function or dysfunction? Oncogene 43(5), 295\u2013303 (2024).","journal-title":"Oncogene"},{"issue":"2","key":"81611_CR56","doi-asserted-by":"publisher","first-page":"56","DOI":"10.31083\/j.fbl2902056","volume":"29","author":"D Lin","year":"2024","unstructured":"Lin, D. et al. FOXO3a induces myocardial fibrosis by Upregulating Mitophagy. Front. Biosci. (Landmark Ed). 29(2), 56 (2024).","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"81611_CR57","doi-asserted-by":"crossref","unstructured":"Izquierdo, M. C. et al. Hepatic FoxOs link insulin signaling with plasma lipoprotein metabolism through an apolipoprotein M\/sphingosine-1-phosphate pathway. J. Clin. Investig. 132(7) (2022).","DOI":"10.1172\/JCI146219"},{"issue":"1","key":"81611_CR58","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41420-023-01681-x","volume":"9","author":"S Xiao","year":"2023","unstructured":"Xiao, S. et al. The role of sphingosine-1-phosphate in autophagy and related disorders. Cell. Death Discov. 9(1), 380 (2023).","journal-title":"Cell. Death Discov."},{"key":"81611_CR59","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.pupt.2019.04.002","volume":"56","author":"S Jiang","year":"2019","unstructured":"Jiang, S. et al. Dual role of autophagy\/mitophagy in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 56, 116\u2013125 (2019).","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"12","key":"81611_CR60","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/cns.12325","volume":"20","author":"RY Shi","year":"2014","unstructured":"Shi, R. Y. et al. BNIP3 interacting with LC3 triggers excessive mitophagy in delayed neuronal death in stroke. CNS Neurosci. Ther. 20(12), 1045\u20131055 (2014).","journal-title":"CNS Neurosci. Ther."},{"issue":"2","key":"81611_CR61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/07853890.2017.1417631","volume":"50","author":"DA Chistiakov","year":"2018","unstructured":"Chistiakov, D. A. et al. The role of mitochondrial dysfunction in cardiovascular disease: a brief review. Ann. Med. 50(2), 121\u2013127 (2018).","journal-title":"Ann. Med."},{"issue":"1","key":"81611_CR62","doi-asserted-by":"publisher","first-page":"8329","DOI":"10.1038\/s41467-023-44109-x","volume":"14","author":"N Thomas","year":"2023","unstructured":"Thomas, N. et al. Sphingosine-1-phosphate suppresses GLUT activity through PP2A and counteracts hyperglycemia in diabetic red blood cells. Nat. Commun. 14(1), 8329 (2023).","journal-title":"Nat. Commun."},{"key":"81611_CR63","doi-asserted-by":"publisher","first-page":"12086","DOI":"10.1038\/ncomms12086","volume":"7","author":"K Sun","year":"2016","unstructured":"Sun, K. et al. Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia. Nat. Commun. 7, 12086 (2016).","journal-title":"Nat. Commun."},{"issue":"2","key":"81611_CR64","first-page":"51","volume":"80","author":"JE Ziello","year":"2007","unstructured":"Ziello, J. E., Jovin, I. S. & Huang, Y. Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J. Biol. Med. 80(2), 51\u201360 (2007).","journal-title":"Yale J. Biol. Med."},{"key":"81611_CR65","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fphar.2017.00326","volume":"8","author":"A Xiong","year":"2017","unstructured":"Xiong, A. & Liu, Y. Targeting hypoxia inducible factors-1\u03b1 as a novel therapy in fibrosis. Front. Pharmacol. 8, 326 (2017).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"81611_CR66","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jjcc.2022.09.002","volume":"81","author":"T Sato","year":"2023","unstructured":"Sato, T. & Takeda, N. The roles of HIF-1\u03b1 signaling in cardiovascular diseases. J. Cardiol. 81(2), 202\u2013208 (2023).","journal-title":"J. Cardiol."},{"key":"81611_CR67","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.mam.2015.12.004","volume":"47-48","author":"EP Cummins","year":"2016","unstructured":"Cummins, E. P. et al. The role of HIF in immunity and inflammation. Mol. Aspects Med. 47\u201348, 24\u201334 (2016).","journal-title":"Mol. Aspects Med."},{"issue":"3","key":"81611_CR68","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1038\/oncsis.2016.13","volume":"5","author":"P Bouquerel","year":"2016","unstructured":"Bouquerel, P. et al. Essential role for SphK1\/S1P signaling to regulate hypoxia-inducible factor 2\u03b1 expression and activity in cancer. Oncogenesis 5(3), e209 (2016).","journal-title":"Oncogenesis"},{"issue":"1","key":"81611_CR69","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41392-023-01652-9","volume":"8","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets. Signal Transduct. Target. Ther. 8(1), 431 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"81611_CR70","doi-asserted-by":"publisher","first-page":"104533","DOI":"10.1016\/j.isci.2022.104533","volume":"25","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Pharmacological inhibition of sphingolipid synthesis reduces ferroptosis by stimulating the HIF-1 pathway. iScience 25(7), 104533 (2022).","journal-title":"iScience"},{"key":"81611_CR71","doi-asserted-by":"crossref","unstructured":"Quinville, B. M. et al. A comprehensive review: sphingolipid metabolism and implications of disruption in sphingolipid homeostasis. Int. J. Mol. Sci. 22(11) (2021).","DOI":"10.3390\/ijms22115793"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81611-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81611-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81611-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T16:08:27Z","timestamp":1733414907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81611-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81611"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81611-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30379"}}